Cytosorbents (CTSO) Cash from Investing Activities Growth (3y) (2013 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 17.83% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -26.99% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -44.28% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -6.23% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -32.54% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -68.12% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 18.69% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 37.39% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -17.67% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | -63.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.18% |
| Mar 31, 2026 | 59.31% |
| Dec 31, 2025 | -12.19% |
| Sep 30, 2025 | 27.58% |
| Jun 30, 2025 | 69.57% |
| Mar 31, 2025 | 61.87% |
| Dec 31, 2024 | 57.99% |
| Sep 30, 2024 | 33.52% |
| Jun 30, 2024 | 50.56% |
| Mar 31, 2024 | 40.61% |
| Dec 31, 2023 | 20.07% |
| Sep 30, 2023 | 13.93% |
| Jun 30, 2023 | 31.66% |
| Mar 31, 2023 | -10.32% |
| Dec 31, 2022 | 20.05% |
| Sep 30, 2022 | -31.46% |
| Jun 30, 2022 | -142.80% |
| Mar 31, 2022 | -21.37% |
| Dec 31, 2021 | -72.93% |
| Sep 30, 2021 | -54.45% |